Global Bevacizumab Biosimilar Market Size By Type (100mg, 400mg), By Application (Colorectal Cancer, Lung Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Bevacizumab Biosimilar Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 4.9 billion by 2031, expanding at a CAGR of 18.0% during the forecast period of 2023–2031. The rapid market growth is fueled by the increasing prevalence of cancers such as colorectal, lung, and renal cancer, combined with growing healthcare cost-containment efforts across both developed and emerging economies. Bevacizumab biosimilars, being cost-effective alternatives to the original biologic, are gaining traction owing to patent expirations, greater regulatory approvals, and rising global adoption of biosimilars in oncology treatment regimes.

Drivers:

1. Rising Cancer Prevalence:

The global burden of cancer is increasing, with bevacizumab indicated for multiple tumor types. As cancer treatment becomes more targeted and personalized, bevacizumab biosimilars offer an effective and affordable therapeutic option.

2. Patent Expirations and Regulatory Support:

The expiration of patents for the original bevacizumab (Avastin®) has opened the door for biosimilar manufacturers. Regulatory agencies like the FDA and EMA are streamlining approval processes, encouraging the development and adoption of biosimilars.

3. Growing Demand for Cost-Effective Oncology Therapies:

Healthcare providers and payers are increasingly prioritizing cost-effective treatment options. Bevacizumab biosimilars offer substantial savings, supporting widespread adoption in both public and private healthcare settings.

Restraints:

1. Stringent Regulatory and Clinical Requirements:

Despite streamlined pathways, biosimilars must still meet rigorous clinical trial and comparability standards. This increases time-to-market and development costs for manufacturers.

2. Limited Physician and Patient Awareness:

In certain markets, physicians and patients remain skeptical about biosimilar efficacy and safety. This hesitance can slow market penetration despite regulatory approvals and cost advantages.

Opportunity:

1. Market Expansion in Emerging Economies:

Countries across Asia-Pacific, Latin America, and the Middle East are expanding access to biologics and biosimilars through healthcare reforms and public health initiatives. These regions represent untapped potential for biosimilar growth.

2. Strategic Collaborations and Licensing:

Pharmaceutical companies are increasingly partnering to develop, manufacture, and distribute bevacizumab biosimilars, accelerating market access and distribution networks globally.

Market by System Type Insights:

The Oncology Biosimilars segment, within which bevacizumab biosimilars fall, led the market in 2023. This dominance is driven by the high usage of bevacizumab in treating solid tumors like colorectal, non-small cell lung, and glioblastoma. As more oncology-focused biosimilars gain approval, this segment will continue to witness robust growth.

Market by End-use Insights:

Hospitals and Oncology Centers emerged as the leading end-users in 2023, accounting for over 60% of market revenue. Bevacizumab biosimilars are typically administered in clinical settings that specialize in cancer care. The retail pharmacy segment is expected to grow steadily as biosimilar prescription models expand in outpatient settings.

Market by Regional Insights:

North America dominated the market in 2023 due to early regulatory approvals, strong reimbursement systems, and the rapid adoption of biosimilars across major healthcare institutions. Asia-Pacific is projected to register the highest growth rate during the forecast period, supported by growing cancer incidence, increasing affordability, and evolving healthcare policies that favor biosimilars in countries like China and India.

Competitive Scenario:

Key players in the global bevacizumab biosimilar market include Pfizer Inc., Amgen Inc., Samsung Bioepis, Biocon Biologics Ltd., Roche (Genentech), Mylan N.V., Celltrion Healthcare, and Coherus BioSciences. These companies are focusing on product approvals, regional expansions, and pricing strategies to secure competitive advantages.

In 2023, Biocon Biologics received FDA approval for its bevacizumab biosimilar, enhancing its oncology pipeline in the U.S.

Pfizer expanded market access to its biosimilar product in the EU and Latin America in 2024.

Samsung Bioepis announced a strategic manufacturing collaboration with a leading contract manufacturer in 2025 to meet increasing global demand.

Scope of Work – Global Bevacizumab Biosimilar Market

Key Market Developments:

2023 – Biocon Biologics secured U.S. FDA approval for its bevacizumab biosimilar (Yesafili), targeting colorectal and lung cancers.

2024 – Coherus BioSciences partnered with a global distributor to expand its biosimilar portfolio across Europe and Asia.

2025 – Samsung Bioepis initiated a biosimilar R&D center in South Korea focused on oncology biosimilars including bevacizumab.

FAQs:

1. What is the current market size of the Global Bevacizumab Biosimilar Market?

The Global Bevacizumab Biosimilar Market was valued at USD 1.3 billion in 2023.

2. What is the major growth driver of the Global Bevacizumab Biosimilar Market?

The primary growth driver is the increasing demand for cost-effective cancer therapies due to rising global cancer incidence.

3. Which is the largest region during the forecast period in the Global Bevacizumab Biosimilar Market?

North America currently leads the market, but Asia-Pacific is expected to witness the fastest growth during the forecast period.

4. Which segment accounted for the largest market share in Global Bevacizumab Biosimilar Market?

The Oncology Biosimilars segment dominated the market in 2023.

5. Who are the key market players in the Global Bevacizumab Biosimilar Market?

Key players include Pfizer Inc., Amgen Inc., Biocon Biologics, Samsung Bioepis, Mylan N.V., and Coherus BioSciences.